MedTrace Logo

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

NCT01961115 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-06-08

Study results available
· View outcomes & findings →

Summary

This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma.

Conditions

  • Mucosal Melanoma
  • Recurrent Melanoma
  • Recurrent Uveal Melanoma
  • Stage IIIA Skin Melanoma
  • Stage IIIA Uveal Melanoma
  • Stage IIIB Skin Melanoma
  • Stage IIIB Uveal Melanoma
  • Stage IIIC Skin Melanoma
  • Stage IIIC Uveal Melanoma
  • Stage IV Skin Melanoma
  • Stage IV Uveal Melanoma

Interventions

DRUG

Epacadostat

Given PO

BIOLOGICAL

MELITAC 12.1 Peptide Vaccine

Given ID/SC

Sponsors & Collaborators

  • Incyte Corporation

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Virginia

    collaborator OTHER

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Craig Slingluff · Cancer Immunotherapy Trials Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-13
Primary Completion
2016-10-31
Completion
2017-05-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01961115 on ClinicalTrials.gov